Home > Resources > Whitepapers > Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

Medical

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

July 13, 2023

Bispecific Antibodies Unleashed
Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies offers industry-leading cGMP contract manufacturing services for recombinant proteins, vaccines and monoclonal antibodies, operating sites in Billingham, UK, Research Triangle Park, North Carolina, USA and College Station, Texas, USA. FUJIFILM Diosynth Biotechnologies has a long track record in enabling customers to improve the cost-effectiveness and profitability of new therapies by providing fast-track progress into and through their clinical development program, validation and commercialization.

OTHER WHITEPAPERS
news image

Eliminate Noisy Oxygen Measurements in Bioreactors

whitePaper | March 27, 2023

Controlling the dissolved oxygen level in fermentation vessels and bioreactors is vital to maximizing production yield and ensuring high end-product quality.

Read More
news image

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Read More
news image

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Read More
news image

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Read More
news image

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

Read More
news image

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Read More

Eliminate Noisy Oxygen Measurements in Bioreactors

whitePaper | March 27, 2023

Controlling the dissolved oxygen level in fermentation vessels and bioreactors is vital to maximizing production yield and ensuring high end-product quality.

Read More

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Read More

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Read More

Bioanalytical Techniques to Advance Biosimilars Development

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.

Read More

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic. 

Read More

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Read More
More Whitepapers

Spotlight

FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies offers industry-leading cGMP contract manufacturing services for recombinant proteins, vaccines and monoclonal antibodies, operating sites in Billingham, UK, Research Triangle Park, North Carolina, USA and College Station, Texas, USA. FUJIFILM Diosynth Biotechnologies has a long track record in enabling customers to improve the cost-effectiveness and profitability of new therapies by providing fast-track progress into and through their clinical development program, validation and commercialization.

Events